Therefore, as a prediction marker for therapeutic efficacy in patients, the number and level of CD11c expression in CD11c+ CD8+ T cells in blood would predict the quality of intratumor CTLs in cancer patients having immunotherapy. Here, ITGAX is linked to cancer.